Yu Lihua, Teng Fei, Jiang Ming, Guo Jia
Suzhou Institute, Tongji University, Suzhou 215000, Jiangsu, China.
Sheng Wu Gong Cheng Xue Bao. 2019 May 25;35(5):880-891. doi: 10.13345/j.cjb.180481.
A simple, robust and highly sensitive TB-ARMS method based on qPCR technique was developed to detect kras mutations. The technique was evaluated, and its clinical application was investigated. Mutation specific primers for eight common kras mutations and wild type gene targeted blockers were designed and optimized. Moreover, a mutant-enriched condition was used in to improve the sensitivity and specificity of mutation detection. Constructed plasmids carrying mutant kras genes, as well as confirmed wild type genomic DNA, were used as standard samples for evaluation of the methodology. The performance of our new method was validated by comparing the results of our method with that of a commercial kras kit in testing 40 clinical samples. Preoperative plasma samples, as well as paired tissue samples, were tested in parallel for evaluation of its clinical application. We have developed a new TB-ARMS method for kras mutation detection that can detect minor mutant alleles with a frequency as low as 0.01% in a heterogeneous sample. We have successfully demonstrated its 0.01% detection sensitivity with highly specific mutant amplification in conjunction with selective wild type suppression by blocker under a mutant-enriched reaction condition. We also showed that our TB-ARMS method was more accurate than the commercial kras kit, which is widely used presently. Furthermore, we have validated our method as an efficient liquid biopsy method, and the results of the plasma DNA detection with our TB-ARMS method were in consistent with the sequencing results of paired tissue samples. In conclusion, our TB-ARMS qPCR method could be effectively applied in kras mutation test for clinical tissue samples, as well as for liquid biopsy samples such as plasma.
开发了一种基于qPCR技术的简单、稳健且高度灵敏的结核分枝杆菌扩增阻滞突变系统(TB-ARMS)方法来检测kras突变。对该技术进行了评估,并研究了其临床应用。设计并优化了针对8种常见kras突变的突变特异性引物和野生型基因靶向阻断剂。此外,采用突变富集条件来提高突变检测的灵敏度和特异性。携带突变kras基因的构建质粒以及经确认的野生型基因组DNA用作评估该方法的标准样品。通过将我们方法的结果与商业kras试剂盒在检测40份临床样品中的结果进行比较,验证了我们新方法的性能。对术前血浆样品以及配对的组织样品进行平行检测,以评估其临床应用。我们开发了一种用于kras突变检测的新型TB-ARMS方法,该方法能够在异质样品中检测频率低至0.01%的次要突变等位基因。在突变富集反应条件下,通过高特异性的突变扩增结合阻断剂对野生型的选择性抑制,我们成功证明了其0.01%的检测灵敏度。我们还表明,我们的TB-ARMS方法比目前广泛使用的商业kras试剂盒更准确。此外,我们已将我们的方法验证为一种有效的液体活检方法,并且我们的TB-ARMS方法检测血浆DNA的结果与配对组织样品的测序结果一致。总之,我们的TB-ARMS qPCR方法可有效地应用于临床组织样品以及血浆等液体活检样品的kras突变检测。